BCN BIOSCIENCES LLC

Pasadena, CA · Biotech · Private

BCN057, a small molecule therapeutic that activates Wnt-β catenin signaling to accelerate intestinal epithelial repair and mitigate acute radiation-induced gastrointestinal syndrome (RIGS)

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · bcnbio.com

Sector: Biotech
Headquarters: Pasadena, CA
Total capital: $10.4M

Federal grants: $4.2M; 6 awards · 2019–2025; Rank in peer group#176 of 502
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $6.2M; 1 award · Health and Human S; Rank in Biotech#72 of 4373
Granted patents: 0; 1 pending

Capital timeline

Latest events

Jun 2025Federal grantHealth and Human S · Phase II · Mitigation of Radiation Induced Gastrointestinal Syndrome.$986K
Aug 2024Federal grantHealth and Human S · Phase II · Mitigation of Radiation Induced Gastrointestinal Syndrome.$1M
Aug 2023Federal grantHealth and Human S · Phase II · Mitigation of Radiation Induced Gastrointestinal Syndrome.$1M
Jun 2020Federal grantHealth and Human S · Phase I · BCN057 as a mitigator of Radiation Induced Gastrointestinal Syndrome$300K
Jul 2019Federal grantHealth and Human S · Phase I · BCN057 as a mitigator of Radiation Induced Gastrointestinal Syndrome$600K
Jun 2019Federal grantHealth and Human S · Phase I · BCN057 as a mitigator of Radiation Induced Gastrointestinal Syndrome$300K
May 2015Federal contractHealth and Human S · Igf::ot::igf Development Of Medical Countermeasures To Mitigate And/or Treat Radiation-induced Lung Injury After A Radiological/nuclear Incident)$6.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grants#176 · top 35%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 1

PendingOrally Available Light-independent Antineoplastic CompoundsUSPTOApplication PCTUS2007014517

DYNAVAX TECHNOLOGIES CORPORATIONSimilar federal contract value in Biotech · $7.1M in contracts
MEDIGEN, INC.Similar federal contract value in Biotech · $7M in contracts
REJUVENATE BIO INCSimilar federal contract value in Biotech · $6.3M in contracts
PAI LIFE SCIENCES INCSimilar federal contract value in Biotech · $5.8M in contracts
60 DEGREES PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $5.8M in contracts
FABRICO TECHNOLOGY, INC.Similar federal contract value in Biotech · $5.6M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.